Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 4,379 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-428, Nivolumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Scottsdale, Arizona • Sacramento, California • Chicago, Illinois + 4 more
Conditions
Lung Cancer
Interventions
biologic sample preservation procedure
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
2,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
431
States / cities
Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 283 more
Completed Phase 2 Interventional Results available

Study of Arsenic Trioxide in Small Cell Lung Cancer

NCT01470248
Conditions
Lung Cancer, Cancer of Lung, Pulmonary Cancer, Pulmonary Neoplasms, Carcinoma, Small Cell
Interventions
Arsenic Trioxide
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma, Mismatch Repair Deficiency, Refractory Colorectal Carcinoma, Refractory Lung Carcinoma, Refractory Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Danvatirsen, Durvalumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lung Cancer
Interventions
Paclitaxel, Carboplatin, Bevacizumab, Pemetrexed Disodium Heptahydrate
Drug · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
434
States / cities
Anniston, Alabama • Fairbanks, Alaska • Fairfield, California + 312 more
Conditions
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
Interventions
BI 765049, ezabenlimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 9 more
Conditions
Lung Cancer
Interventions
technetium-99
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
12
States / cities
Lewes, Delaware • Newark, Delaware • Evanston, Illinois + 9 more
Conditions
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Survey Administration
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
134 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Conditions
Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Non-small Cell Lung Cancer
Interventions
ilixadencel, Pembrolizumab
Biological · Drug
Lead sponsor
Mendus
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Coral Gables, Florida • Iowa City, Iowa • Louisville, Kentucky + 2 more
Conditions
Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Ovarian Neoplasms
Interventions
RO7515629, tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Nashville, Tennessee
Conditions
Non Small Cell Lung Cancer, c-MET
Interventions
Telisotuzumab Vedotin, Docetaxel
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
50
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 46 more
Conditions
Stage IV NSCLC
Interventions
Poly ICLC, IVIG
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
Interventions
BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab, mFOLFOX6, BBO-10203, mFOLFIRINOX, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Industry
Eligibility
18 Years and older
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 12 more
Terminated Phase 2 Interventional Results available

Malignant Pleural Effusion With ZD6474

NCT00402896
Conditions
Lung Cancer, Pleural Effusion
Interventions
ZD6474
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Non-small Cell Lung Cancer
Interventions
Durvalumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Tucson, Arizona • Tampa, Florida • Royal Oak, Michigan
Conditions
Cachexia; Cancer, Non Small Cell Lung Cancer
Interventions
Anamorelin Hydrochloride, Placebo Oral Tablet
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
24
States / cities
Tucson, Arizona • Little Rock, Arkansas • Riverside, California + 21 more
Conditions
Kidney Neoplasms, Kidney Cancer, Pneumothorax, FLCN Protein, Human
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Non-small Cell Lung Cancer Stage IIIC, Non-small Cell Lung Cancer Stage IV, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Unresectable
Interventions
Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment., Standard of Care
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
4
States / cities
Chico, California • Marysville, California • Sacramento, California + 1 more
Conditions
Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer
Interventions
Niraparib, TSR-042, Carboplatin-Paclitaxel, Bevacizumab, TSR-022, Carboplatin-Pemetrexed, Carboplatin-Nab-Paclitaxel
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
8
States / cities
Scottsdale, Arizona • Encinitas, California • San Marcos, California + 5 more
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
suramin, docetaxel, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cetuximab, bortezomib
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
BMS-986012, Carboplatin, Etoposide, Nivolumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Birmingham, Alabama • Hackensack, New Jersey • Durham, North Carolina + 4 more
Conditions
Non Small Cell Lung Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina • Dallas, Texas + 1 more
Conditions
Non-small Cell Lung Cancer
Interventions
Cetuximab
Drug
Lead sponsor
Lecia V. Sequist
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts